MTL 005

Drug Profile

MTL 005

Alternative Names: MTL-005

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Morvus Technology
  • Developer MorEx Development Partners
  • Class Metalloporphyrins; Radiation-sensitising agents; Radiosensitisers
  • Mechanism of Action Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Breast cancer
  • No development reported Head and neck cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Head-and-neck-cancer in United Kingdom (Parenteral, Injection)
  • 26 Mar 2015 MTL 005 is available for licensing as of 26 Mar 2015. http://www.morexdevelopments.com/partnering.html
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top